Company news
Prelude Therapeutics Incorporated news in 2020
Prelude Therapeutics Incorporated's news releases, calls and decks from 2020, newest first.
Prelude Therapeutics Announces Third Quarter 2020 Financial Results
November 9, 2020
Prelude Therapeutics Announces Dosing of First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic Malignancies
September 29, 2020
Prelude Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
September 28, 2020
Prelude Therapeutics Announces Pricing of Initial Public Offering
September 23, 2020